Investors & Media


HomeInvestors & MediaNews

ABL Bio to Present Two Abstracts at the AACR Annual Meeting 2021

​- Preclinical data suggest that ‘Grabody-T’ enhances anti-cancer activity without severe liver toxicity

Preclinical studies indicate ABL501 (PD-L1xLAG-3 BsAb) has potential to enhance antitumor efficacy and overcome the resistance to current immunotherapies


March 11, 2021 – ABL Bio, Inc., a South Korean biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced it will make two poster presentations at the virtual American Association for Cancer Research(AACR) 2021 Annual Meeting.


The presentations will focus on the preclinical data of ‘Grabody-T,’ a 4-1BB engaging bispecific antibody platform that has demonstrated anti-tumor efficacy, while successfully eliminating 4-1BB related liver toxicity issues. ABL will also present new data regarding ABL501, a bispecific antibody targeting PD-L1 and LAG-3 checkpoint pathways.


The details of the presentation are as follows:


Title: A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format

Abstract Control Number: 1250

Session Type: E-Poster Session

Session Title: Therapeutic Antibodies, Including Engineered Antibodies

Permanent Abstract Number: 1850


Title: ABL501, PD-L1 X LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1

Abstract Control Number: 2255

Session Type: E-Poster Session

Session Title: Immune Checkpoints

Permanent Abstract Number: 1633



About ABL Bio

ABL Bio, Inc. (KOSDAQ: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit 

ABL Bio to Present New Preclinical Data from its Parkinson’s Program at Virtual AD/PD 2021
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors